Key Highlights

  • Net asset value was $206.92 as of 17 November 2026, with net Assets of $10,946,026,427.
  • The fund tracks the NYSE Biotechnology index across 243 holdings.
  • Gilead Sciences, Amgen and Vertex Pharmaceuticals are the largest positions.
  • The expense ratio is 0.44% and distributions are paid quarterly.

The iShares Biotechnology ETF (NASDAQ:IBB) tracks an index of U.S.-listed biotechnology equities focused on the Research and Development of therapeutic treatments. As of 17 November 2026, the net asset value was $206.92 and net assets totaled $10,946,026,427.

Fund Detail

Information

Exchange

NASDAQ

Benchmark index

NYSE Biotechnology Index

Net asset value (17 Nov 2026)

$206.92

Daily NAV change

-$1.20 (-0.57%)

Net assets

$10,946,026,427

Number of holdings

243

Expense ratio

0.44%

30-day SEC Yield (31 Oct 2026)

-0.15%

12-month trailing yield

0.16%

Distribution frequency

Quarterly

Fund inception

5 February 2001

Index Design and Scope

The fund follows the NYSE Biotechnology Index and holds 243 U.S.-listed companies engaged in developing therapeutic treatments. The portfolio includes established biopharmaceutical companies alongside smaller developers, and the index is not capped, so position sizes reflect the relative market values of the holdings more directly than in a capped benchmark.

Largest Positions

Gilead Sciences is the largest holding at 9.18% of market value, followed by Amgen at 8.62% and Vertex Pharmaceuticals at 7.91%. Regeneron (6.69%), Moderna (5.58%) and argenx (3.75%) rank next. Natera, Biogen, BeOne Medicines and Revolution Medicines complete the top ten, which together account for about 52% of the portfolio.

Yield, Distributions and Costs

The fund distributes income quarterly. The 30-day SEC yield was -0.15% and the 12-month trailing yield was 0.16%, both measured as of 31 October 2026. The expense ratio is 0.44%, equal to the management fee. The prospectus notes that biotechnology companies depend on regulatory approvals and that the fund's concentration in one industry can make it more volatile than the broader market.

Final Word

The iShares Biotechnology ETF provides a focused view of therapeutic developers, with 243 holdings and quarterly distributions. The index design, the leading positions in a few large companies and the 0.44% expense ratio are the central elements of the fund's profile covered here.